MiMedx boldly claims on its website that it has “distributed more than 1 million allografts to date with zero reported adverse reactions attributed to our products”. Yet, according to a lawsuit filed earlier this month, an Epifix patient suffered an adverse reaction so severe that she was left permanently maimed. Read More
This report specifically exposes how MiMedx relabels product as a means to provide kickbacks and induce sales at the expense of patients. Read More
This report specifically exposes severe undisclosed manufacturing problems and contamination risks. Even though FDA investigators identified issues that “pose a significant risk to the recipient”, the company is marketing unapproved products produced by these facilities for risky experimental indications such as spinal injections. Unsuspecting patients are being defrauded through false advertisements used by dubious clinics to entice them into receiving the injections. Because these activities appear to put patients in danger, we believe the FDA has no choice but to immediately intervene. Read More
We are writing you to express our belief that the ongoing fraud at MiMedx must be stopped immediately and our opinion that you are uniquely positioned to do so. You have an important opportunity to use your position as a MiMedx Director to protect your legacy and reputation. Read More
We are writing to express our concerns about the risks of serious and pervasive fraud at Mimedx Group, Inc. and your firm’s audit thoroughly testing these risks in light of facts and allegations that have emerged. Read More
Dear Senator Isakson, We are writing you to express our concerns about your role in the Department of Veterans Affairs Office of Inspector General’s (VA OIG) investigation as it relates to your large donors, MiMedx Group, and your longtime personal friend, MiMedx CEO Parker “Pete” Petit. Read More
We see large undiscounted channel stuffing and kickback risks lurking beneath the surface at MiMedx (NASDAQ: MDXG) Read More